Physician
Coral Medical Services, PLLC
Coral Medical Services, PLLC was paid $2.17M by Medicaid between Aug 2018 and Dec 2024, across 41 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 24% of everything it billed.
33Billing provider infoCORAL MEDICAL SERVICES, PLLC
DALLAS, TX 75218
DALLAS, TX 75218
33aNPI1952613465assigned 07/13/2010
33bProvider typeFamily Medicine Physician
28Total paid$2.17M
24GClaims101,215
24DCodes billed41
24AFirst – last monthAug 2018 – Dec 2024
Compared with peers
Next to other Family Medicine Physician providers in Texas
Rank by total paid#51 of 1,204
Median peer was paid$31K
This provider vs. median70×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 57 | $1K | |
| 2020 | 1,680 | $35K | |
| 2021 | 18,109 | $347K | |
| 2022 | 27,724 | $573K | |
| 2023 | 29,077 | $659K | |
| 2024incomplete | 24,568 | $554K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 24% | 11,546 | 10,039 | $526K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 18% | 9,422 | 8,276 | $393K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 14% | 9,233 | 7,553 | $307K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 9.1% | 14,824 | 6,630 | $197K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 6.5% | 10,710 | 9,468 | $141K |
| 92567 | 5.4% | 12,173 | 10,534 | $117K | |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 5.1% | 1,588 | 1,410 | $110K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 5.0% | 5,782 | 5,034 | $109K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 3.6% | 1,023 | 916 | $78K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 3.0% | 931 | 860 | $65K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 2.0% | 3,928 | 1,931 | $43K |
| 87807 | <1% | 1,556 | 1,393 | $16K |
29 more codes
| 99203 | Doctor's office visit, new patient (routine) | <1% | 279 | $15K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 169 | $14K |
| 86580 | <1% | 1,671 | $12K | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 191 | $6K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 4,738 | $5K |
| 83655 | <1% | 527 | $4K | |
| 81002 | <1% | 1,476 | $4K | |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 28 | $2K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 84 | $2K |
| 99382 | <1% | 15 | $1K | |
| 99050 | <1% | 97 | $1K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 20 | $783.20 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 5,001 | $598.71 |
| 92552 | <1% | 85 | $574.92 | |
| 90461 | <1% | 270 | $462.07 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 169 | $409.16 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 24 | $223.89 |
| 90686 | <1% | 685 | $215.81 | |
| 90734 | <1% | 89 | $154.72 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 2,485 | $99.75 |
| 81025 | <1% | 13 | $93.99 | |
| 90715 | <1% | 15 | $62.39 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 24 | $0.85 |
| 90620 | 0% | 13 | $0.00 | |
| 90696 | 0% | 12 | $0.00 | |
| 90710 | 0% | 68 | $0.00 | |
| 90670 | 0% | 98 | $0.00 | |
| 90649 | 0% | 95 | $0.00 | |
| 90633 | 0% | 58 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialORTEGA, CHARLES (ADMINISTRATOR)